Alzheimer’s Disease (AD) is characterized by the presence of extracellular plaques and intracellular neurofibrillary tangles(NFTs) in the brain. The major protein component of these plaques is beta amyloid peptide(Aβ), a 40 to 43 amino acid peptide cleaved from amyloid precursor protein by β-secretase and a putative γ-secretase. Increased release of the ‘longer forms’ of Aβ peptide, Aβ42 or Aβ43, which have a greater tendency to aggregate than Aβ40, occurs in individuals expressing certain genetic mutations, expressing certain ApoE alles, or may involve other, still undiscovered, factors, Many researchers theorize that it is this increased release of Aβ42/Aβ43 which leads to the abnormal deposition of Aβ and the associated neurotoxicity in the brains of affected individuals. For research use only, not for use in diagnostic procedures.
- application:
- IHC, WB
- Catalog number:
- 18580
- Datasheet:
- formulation:
- Lyophilized product from 1% BSA in PBS containing 0.05% NaN3
- immunogen:
- Synthetic peptide for C-terminal of Human Amyloidβ (1-40) (MVGGVV)
- notes:
- For research use only, not for use in diagnostic procedures.
The datasheet for this product (see above) is intended to serve as an example only. Please refer to the datasheet provided with the antibody for precise details. - Other names:
- Aβ, Amyloid beta, A-beta
- Protocol:
- purification:
- Affinity Purified with antigen peptide
- size:
- 50 µg
- specificity:
- Human Amyloid Beta (1-40) Aβ specific. Not cross-react with human Amyloid Beta Aβ (1-42) or (1-43).
- storage:
- Lyophilized product, 5 years at 2 - 8°C; Solution, 2 years at -20°C.
- Species:
- Human
- Host:
- Rabbit
- Additional Info:
- References:
- Related Articles:
